Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | LDHA | P00338 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19200474 | 0.88 | SLC6A4 (0.49) | SLC6A4CYP2C19CYP1A2CYP2D6LDHA | |
| SCHEMBL7329609 | 0.87 | SLC6A4 (0.46) | SLC6A4CYP2C19CYP1A2CYP2D6LDHA | |
| SCHEMBL17038559 | 0.87 | SLC6A4 (0.43) | SLC6A4CYP2C19CYP1A2CYP2D6LDHA | |
| SCHEMBL3777215 | 0.79 | LDHA (0.46) | SLC6A4CYP2C19CYP1A2CYP2D6LDHA | |
| SCHEMBL10495976 | 0.78 | MMP1 (0.41) | — | |
| SCHEMBL9502392 | 0.78 | MMP1 (0.41) | — | |
| SCHEMBL7276240 | 0.77 | MMP1 (0.41) | — | |
| SCHEMBL7276267 | 0.77 | MMP1 (0.41) | — | |
| SCHEMBL9407674 | 0.76 | LDHA (0.46) | SLC6A4CYP2C19CYP1A2CYP2D6LDHA | |
| SCHEMBL18647235 | 0.75 | LDHA (0.51) | SLC6A4LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452215-B2 | Bourvadin derivatives and therapeutic uses thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150238562-A1 | BOURVADIN DERIVATIVES AND THERAPEUTIC USES THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238562-A1 | BOURVADIN DERIVATIVES AND THERAPEUTIC USES THEREOF | RPL27, EIF4E, RPL30 | SLC6A4 4467/4885CYP2C19 3573/4885CYP1A2 4205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.